Fennec Pharmaceuticals (FENC) Gross Margin (2023 - 2025)
Fennec Pharmaceuticals filings provide 3 years of Gross Margin readings, the most recent being 55.68% for Q4 2025.
- On a quarterly basis, Gross Margin rose 545.0% to 55.68% in Q4 2025 year-over-year; TTM through Dec 2025 was 71.65%, a 621.0% decrease, with the full-year FY2025 number at 58.3%, down 294.0% from a year prior.
- Gross Margin hit 55.68% in Q4 2025 for Fennec Pharmaceuticals, down from 58.19% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 97.83% in Q1 2024 to a low of 35.67% in Q2 2024.
- Median Gross Margin over the past 3 years was 91.47% (2023), compared with a mean of 78.47%.
- Biggest five-year swings in Gross Margin: plummeted -5988bps in 2024 and later surged 5432bps in 2025.
- Fennec Pharmaceuticals' Gross Margin stood at 92.96% in 2023, then crashed by -46bps to 50.23% in 2024, then rose by 11bps to 55.68% in 2025.
- The last three reported values for Gross Margin were 55.68% (Q4 2025), 58.19% (Q3 2025), and 89.98% (Q2 2025) per Business Quant data.